Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 154   

Articles published

MRK 62.56 -0.26 (-0.41%)
price chart
Stock Pick - Merck & Co. Inc. (MRK)
Merck & Co. Inc. has been consolidating in a bullish flag pattern in the last two weeks after a move of about $6 from the 57 range to around 63 earlier this month.
Merck & Co., Inc. (MRK) Takes Hepatitis C Drug Victrelis Off The US Market
Merck & Co., Inc. (NYSE:MRK) notified the US Food and Drug Administration (FDA) earlier this week that it has decided to no longer sell its hepatitis C drug Victrelis in the US.
TransCelerate BioPharma Welcomes Merck & Co. and Novo Nordisk to its ...
PHILADELPHIA, Jan 27, 2015 (BUSINESS WIRE) -- TransCelerate BioPharma Inc.today announced two new members, Merck & Co. Inc., and Novo Nordisk, to the biopharmaceutical non-profit organization. In addition, TransCelerate has appointed Briggs ...
Trade of the Day: Merck (MRK)
Today's recommendation is for a call trade on Merck & Co., Inc. (MRK), a pharmaceutical company whose key products include Januvia (for diabetes), Zetia (for cholesterol) and Gardasil (vaccine for HPV).
Merck & Co. Inc. (MRK) Closes 0.53% Up on the Day for January 26
Merck & Co. Inc. currently has a total float of 2.85 billion shares and moves 11.44 million a day, on average. The stock opened at $62.58 on January 26 and traded between a low of $62.12 and a high of $62.98.
Merck & Co. Inc. (MRK) Closes 0.41% Down on the Day for January 27
Merck & Co. Inc. currently has a total float of 2.85 billion shares and moves 11.22 million a day, on average. The stock opened at $62.88 on January 27 and traded between a low of $62.13 and a high of $63.02.
Exclusive: Merck funds tests of lower Zilmax doses as seen seeking way to ...
CHICAGO (Reuters) - Merck & Co Inc is funding the testing of lower dosages of its controversial cattle growth drug Zilmax, in a move that livestock experts say is crucial if the company is to resume sales of the product to the U.S.
First Call Rating Update on Merck & Co., Inc.
Merck & Co., Inc. (NYSE:MRK) has been rated as Buy in the consensus recommendation of First Call Corporation, a division of Thomson Reuters.
Stock Watch: Merck & Co. Inc. (NYSE:MRK)
[Business Wire] Merck & Co., Inc. (NYSE:MRK) (TREND ANALYSIS) known as MSD outside the United States and Canada, on behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc., today announced that, in connection with the completion of the ...
Merck & Co. Inc. (NYSE:MRK) Grabs Market Attention With GlaxoSmithKline ...
Merck & Co. Inc. (NYSE:MRK) [Trend Analysis] edged up in afterhours trading session on Monday, after it declared that the Committee for Medicinal Products for Human Use of the European Medicines Agency has accepted a optimistic opinion recommending ...
Merck & Co., Inc. Insider Trading Update  Bar and Graph Report
Merck & Co., Inc. Witness Large Outflow of Money  Stafford Daily